Elvin Ruiz
Psychiatry · New York, NYNPI 1568538379
Payments from drug & device makers
Across 999 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Neos Therapeutics, LP$1K
- Sunovion Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$1K
- plus $8K from 27 others
What the payments were for
- Food & beverage$18,82798%
- Education$3762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 263 | $4,366 |
| Takeda Pharmaceuticals U.S.A., Inc. | 77 | $1,516 |
| Neos Therapeutics, LP | 93 | $1,474 |
| Sunovion Pharmaceuticals Inc. | 90 | $1,450 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $1,205 |
| Lundbeck LLC | 66 | $1,181 |
| Axsome Therapeutics, Inc. | 25 | $939 |
| Supernus Pharmaceuticals, Inc. | 46 | $894 |
| Alkermes, Inc. | 40 | $868 |
| Otsuka America Pharmaceutical, Inc. | 44 | $729 |
| Tris Pharma Inc | 41 | $675 |
| Teva Pharmaceuticals USA, Inc. | 22 | $616 |
| Ironshore Pharmaceuticals Inc. | 26 | $470 |
| Jazz Pharmaceuticals Inc. | 9 | $453 |
| Corium, LLC | 21 | $441 |
| Johnson & Johnson | 15 | $405 |
| Harmony Biosciences LLC | 6 | $220 |
| Brainsway USA Inc | 5 | $208 |
| Almatica Pharma LLC | 9 | $205 |
| Idorsia Pharmaceuticals US Inc | 10 | $169 |
| E.r. Squibb & Sons, L.L.C. | 4 | $120 |
| Arbor Pharmaceuticals, Inc. | 6 | $104 |
| Pfizer | 5 | $96 |
| Biohaven Pharmaceuticals, Inc. | 5 | $80 |
| Azurity Pharmaceuticals, Inc. | 3 | $60 |
| Bausch Health US, LLC | 3 | $41 |
| Aytu Biopharma, Inc. | 3 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Adlon Therapeutics L.p. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Amgen | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,203 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 11 | $15,273 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,577 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 61 | $1,867 |
| Quetiapine Fumarate | 41 | $547 |
| Bupropion XlBupropion Hcl | 28 | $505 |
| Alprazolam | 75 | $455 |
| Clonazepam | 73 | $443 |
| Pregabalin | 25 | $427 |
| Duloxetine Hcl | 26 | $397 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $346 |
| Gabapentin | 16 | $331 |
| Buspirone Hcl | 20 | $316 |
| Zolpidem Tartrate | 67 | $216 |
| Lamotrigine | 38 | $215 |
| Escitalopram Oxalate | 21 | $194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $729 | $15,27311 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $1,516 | $4,57712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New York
- Michael LiebowitzNew York$7.1M
- Paul EderNew York$2.7M
- Lenard AdlerNew York$1.8M
- Ram ShrivastavaNew York$1.8M
- Jonathan KaneNew York$1.8M
- Eric HollanderNew York$1.4M
- William HapworthNew York$1.3M
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Anthony ZoghbiNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.